Fertility-Sparing Treatment in Women with Atypical Hyperplasia/Endometrioid Intraepithelial Neoplasia/ Endometrial Cancer: A Tertiary Cancer Center Experience Atipik Hiperplazi/Endometrioid İntraepitelyal Neoplazi/Endometrial Kanserde Fertilite Koruyucu Tedavi: Bir Üçüncül Kanser Merkezi Deneyimi
Turkish Journal of Reproductive Medicine and Surgery, cilt.6, sa.1, ss.128-134, 2022 (Scopus, TRDizin)
- Yayın Türü: Makale / Tam Makale
- Cilt numarası: 6 Sayı: 1
- Basım Tarihi: 2022
- Doi Numarası: 10.24074/tjrms.2022-92149
- Dergi Adı: Turkish Journal of Reproductive Medicine and Surgery
- Derginin Tarandığı İndeksler: Scopus, TR DİZİN (ULAKBİM)
- Sayfa Sayıları: ss.128-134
- Anahtar Kelimeler: Atypical hyperplasia, endometrial cancer, endometrioid intraepithelial neoplasia, fertility-sparing
- Sağlık Bilimleri Üniversitesi Adresli: Evet
Özet
Objective: The present study aims to evaluate the oncological and obstetric outcomes after fertility-sparing treatment in patients with endometrial atypical hyperplasia (AH), endometrioid intraepithelial neoplasia (EIN), and endometrioid adenocarcinoma (EC). Materials and Methods: We retrospectively analyzed the records of patients with AH/EIN and EC who underwent fertility-preserving treatment in a tertiary gynecological cancer center between February 2014 and July 2020. The median follow-up was 52 (range, 6-75) months. Results: The complete response rate was 75.9%. All of the patients with EC (n=2) had stable disease after the treatment of 6 months. Twenty-two (81.5%) patients of 27 patients with AH/EIN had a complete response after the treatment of 6-12 months. Two of AH/EIN patients progressed to grade 1 endometrioid endometrial cancer, and 3 of AH/EIN patients had stable disease during the 6-month treatment period. The time to complete response was ≤6 months in 13 (59.1%) and >6 months in 9 (40.9%) patients in the AH/EIN group. One patient with AH/EIN after complete response became pregnant spontaneously and she gave a healthy birth. The recurrence rate was 9.1%. Conclusion: Fertility-sparing treatment modalities could be feasible in women with precursor lesions of endometrial carcinoma or low-grade endometrial cancer who want to preserve their fertility within close follow-up.